A Study to Assess Intravenous (IV) Telisotuzumab Adizutecan in Combination With Fluorouracil, Folinic Acid, and Oxaliplatin (FOLFOX) Compared to Standard of Care in Adult Participants With First-Line Metastatic Pancreatic Ductal Adenocarcinoma

← catalyst calendar

NCT07490301 · readout ≤ 1,776 d

Sponsored by AbbVie (industry) · ABBV — their whole pipeline →.

Phase

Phase 2/3

Status

Recruiting

Study type

Interventional

Design

Randomized · None · Treatment

Enrollment

900estimated

Sites

Countries

Australia, Israel, Italy +5

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Dates

each axis at the precision it was filed, with the registry's own basis

Date

Filed

Basis

What it is

Start

2026-04-30

actual

When the study began enrolling

Primary completion

Jun 2031

estimated

The date the last participant is measured for the primary outcome — the readout window

Study completion

Jun 2031

estimated

The whole study's end, after follow-up

First posted

2026-03-24

actual

When this record first appeared on the registry

Results posted

—

When the sponsor posted results to the registry

Record updated

2026-08-14

actual

The sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Conditions

Metastatic Pancreatic Ductal Adenocarcinoma
PDAC

Interventions

Drug: Telisotuzumab adizutecan
Drug: Fluorouracil
Drug: Folinic acid/ Leucovorina
Drug: Oxaliplatin
Drug: Irinotecan

Primary outcomes

what the primary-completion date above is the date OF

Phase 2 and Phase 3: Overall Response (OR) Assessed by Blinded Independent Central Review (BICR) per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1

measured through study completion, approximately 6 years

Phase 3: Overall Survival (OS)

measured through study completion, approximately 6 years

Permalink · ABBV's whole pipeline · Catalyst calendar · Every registered study · What changed